Format

Send to

Choose Destination
Discov Med. 2014 Jul-Aug;18(97):67-77.

State-of-the-art human gene therapy: part I. Gene delivery technologies.

Author information

1
Gene Therapy Center, University of Massachusetts School of Medicine, 368 Plantation St., AS6-2011, Worcester, MA 01605, USA.

Abstract

Safe and effective gene delivery is a prerequisite for successful gene therapy. In the early age of human gene therapy, setbacks due to problematic gene delivery vehicles plagued the exciting therapeutic outcome. However, gene delivery technologies rapidly evolved ever since. With the advancement of gene delivery techniques, gene therapy clinical trials surged during the past decade. As the first gene therapy product (Glybera) has obtained regulatory approval and reached clinic, human gene therapy finally realized the promise that genes can be medicines. The diverse gene delivery techniques available today have laid the foundation for gene therapy applications in treating a wide range of human diseases. Some of the most urgent unmet medical needs, such as cancer and pandemic infectious diseases, have been tackled by gene therapy strategies with promising results. Furthermore, combining gene transfer with other breakthroughs in biomedical research and novel biotechnologies opened new avenues for gene therapy. Such innovative therapeutic strategies are unthinkable until now, and are expected to be revolutionary. In part I of this review, we introduced recent development of non-viral and viral gene delivery technology platforms. As cell-based gene therapy blossomed, we also summarized the diverse types of cells and vectors employed in ex vivo gene transfer. Finally, challenges in current gene delivery technologies for human use were discussed.

PMID:
25091489
PMCID:
PMC4440413
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Discovery Medicine Icon for PubMed Central
Loading ...
Support Center